



Media Contact

Carol Berry

Chief Business Officer, SVP

Caprion, Inc.

cberry@caprion.com or 514.360.3600

Caprion to Present Data on Two New Assays at 2014 AAPS National Biotechnology Conference

*Multiplexed MRM Assay for Mild-Cognitive Impairment and Alzheimer's Disease
and
PK Assay for RLIP76 Protein Measurement in Cancer and Chronic Diseases*

Montreal, Canada – May 15, 2014—Caprion announced today that its proteomics business unit, ProteoCarta™, will be presenting two posters regarding its new Multiple Reaction Monitoring (MRM) Assay for CNS diseases and its new large molecule PK assay for application in clinical cancer and chronic disease research. Data will be presented at the 2014 AAPS National Biotechnology Conference being held in San Diego, California, May 19-21, 2014.

Abstract # T2034

Development of a Mass Spectrometry Based Pharmacokinetic (PK) Assay for the Measurement of RLIP76 Protein and Proteoliposome in Human Serum

Tuesday, May 20th, 10 AM-2:30 PM

Location: Sheraton San Diego Hotel and Marina

Presenter: Laura McIntosh, Ph.D., Vice President, Translational Research, Caprion

Using the RLIP76 protein that is being developed by Terapio¹ as an example, the poster will describe the broad and robust utility of mass spectrometry (MS) for absolute quantitation of biologic and biosimilar drug products in development for different therapeutic areas (oncology, diabetes, cardiovascular, Alzheimer's disease and others).

Abstract #W3079

A Multiplexed MRM Assay for the Measurement of Human CSF Candidate Protein Biomarkers in Control, Mild-Cognitive Impairment and Alzheimer's Disease Patients

Wednesday, May 21st, 10 AM-2:30 PM

Location: Sheraton San Diego Hotel and Marina

Presenter: Lorella Di Donato, Ph.D., Vice President, Scientific Operations, Caprion
The poster will outline study results from our collaboration with the Biomarkers Consortium indicating that the multiplexed MRM assay is reproducible, reliable and allows for potential identification of novel biomarkers for Alzheimer's disease and other CNS disease diagnoses. Additionally, the study results demonstrate the assay's role in monitoring drug safety, efficacy and stratification among pre-symptomatic patients for clinical trials enrollment.

About Caprion

Caprion is the leading provider of proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Its immune monitoring business unit, ImmuneCarta[®], offers proprietary multiparametric flow cytometry for functional analyses of innate and adaptive immune responses. Caprion's proteomics business unit, ProteoCarta[®], offers proprietary gel-free, label-free mass spectrometry (MS) for comprehensive, quantitative and robust comparative measurement of proteins across large sets of biological samples for the discovery and validation of protein biomarkers. Caprion also leverages ProteoCarta[®] to develop its own in-vitro diagnostic products targeting cancer, metabolic and infectious diseases. With research sites in Montreal, Canada and in Menlo Park, CA, Caprion has been providing large-scale proteomics and immune monitoring services to over 50 major pharmaceutical and biotech clients for more than 10 years. Caprion, a privately-held company, is majority owned by Chicago Growth Partners. For more information, please visit www.caprion.com.

1. Research reported in this poster was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number R44AI081356. The content is solely the responsibility of the authors and does not necessarily represent the official views of The National Institutes of Health.